X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price Up 1.9% – Should You Buy?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) shot up 1.9% on Tuesday . The company traded as high as $3.72 and last traded at $3.70. 191,744 shares changed hands during trading, a decline of 43% from the average session volume of 335,343 shares. The stock had previously closed at $3.63.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on XFOR shares. Stifel Nicolaus set a $10.00 price objective on X4 Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 5th. Wall Street Zen lowered shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research note on Monday, December 29th. Finally, Zacks Research lowered shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $34.50.

X4 Pharmaceuticals Stock Up 1.9%

The business’s fifty day moving average price is $3.82 and its two-hundred day moving average price is $3.30. The company has a debt-to-equity ratio of 1.23, a quick ratio of 5.48 and a current ratio of 5.65. The firm has a market capitalization of $323.53 million, a P/E ratio of -0.37 and a beta of 0.41.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.10. The firm had revenue of $1.77 million during the quarter, compared to analyst estimates of $2.05 million. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%. Equities analysts expect that X4 Pharmaceuticals, Inc. will post -0.68 earnings per share for the current fiscal year.

Institutional Trading of X4 Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Rhumbline Advisers grew its stake in X4 Pharmaceuticals by 5.4% during the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after buying an additional 9,690 shares during the last quarter. Two Sigma Investments LP acquired a new stake in X4 Pharmaceuticals in the third quarter worth about $47,000. Bank of America Corp DE grew its stake in shares of X4 Pharmaceuticals by 20.3% during the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after acquiring an additional 22,485 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of X4 Pharmaceuticals by 112.5% during the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock valued at $185,000 after acquiring an additional 51,544 shares in the last quarter. Finally, Palumbo Wealth Management LLC acquired a new position in shares of X4 Pharmaceuticals during the third quarter valued at about $326,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.